Gut bacteria therapy plus chemotherapy for advanced pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This trial tests combining a fecal microbiota transplant (FMT, a procedure to restore healthy gut bacteria) with an investigational immunotherapy (SHR-1701) and standard chemotherapy drugs (nab-paclitaxel and gemcitabine) as first treatment for advanced pancreatic cancer. The goal is to see if this combination slows tumor growth and helps you live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) that is locally advanced or cannot be removed with surgery, and you have not had any prior chemotherapy for this advanced stage.
- You have at least one tumor that can be measured on imaging scans.
- Your blood counts, liver, kidney, heart, and blood clotting functions are within acceptable ranges.
- You are able to swallow capsules.
- You are generally active (able to care for yourself and be up and about more than half of your waking hours).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a healthy bacteria transplant along with chemotherapy and an immunotherapy drug can help people with advanced pancreatic cancer. The treatment aims to boost the body's immune system to fight the cancer better.
This trial tests a new combination of an immunotherapy drug (QL1706) and two chemotherapy medicines (AG) as the first treatment for advanced pancreatic cancer. The goal is to see if the combination can shrink tumors and help patients live longer.
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
This trial tests a new drug, pegcetacoplan, combined with a standard chemotherapy regimen called modified FOLFIRINOX, for people with pancreatic cancer that has spread to other parts of the body. The goal is to see if the combination helps control the cancer better than chemotherapy alone.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
This trial tests a new approach that combines a special type of radiation therapy (called PRaG) with an immunotherapy drug to treat advanced pancreatic cancer that hasn't spread. The goal is to see if this combination can shrink or control the tumor and help you live longer.
Hear when a new Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.